NNNN
Anbio Biotechnology
4.05
+0.25 (+6.58%)
52w low 3.09
44.73 high
2.3% of range
Open
3.81
High
4.26
Low
3.81
Prev Close
3.80
Volume
23.16K
Avg Vol 3M
149.04K
Market Cap
177.76M
Currency
USD
6 Month Trend
—
C--
Chg--
Gap--
Vol--
×avg--
σ--
SMA20--
SMA50--
SMA200--
RSI--
SPY--
DD--
Bench--
Sig--
Hist--
pinned · Esc to release
hover · click to pin · ← → step · drag to zoom · shift-drag to measure
—Context
- Move across the chart.
Company
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Country | Germany |
| Employees | 27 |
| Web | site ↗ |
Performance
1D
+6.58%
5D
+10.05%
1M
-8.16%
3M
-59.05%
6M
-83.95%
YTD
-86.53%
1Y
-82.49%
2Y
--
3Y
--
5Y
--
MAX
-39.46%
Valuation
| P/E Trailing | 25.33x |
| P/E Forward | -- |
| Price / Book | 5.53x |
| Price / Sales | 19.29x |
| EV / EBITDA | -- |
| EPS Trailing | 0.15 |
| Dividend Yield | 0.00% |
| Beta | -- |
Profitability
| Gross Margin | 87.24% |
| Operating Margin | 59.09% |
| Net Margin | 74.06% |
| Return on Equity | 27.05% |
| Return on Assets | 14.66% |
| Revenue Growth | +73.90% |
| Debt / Equity | -- |
| Current Ratio | 344.31x |
Business
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.